STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[Form 4] PTC THERAPEUTICS, INC. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

PTC Therapeutics director reports charitable stock gift

A director of PTC Therapeutics, Inc. (PTCT) reported a bona fide gift of 867 shares of the company’s common stock on 11/20/2025. The transaction was coded as a gift and priced at $0, reflecting that no sale proceeds were received. After this transaction, the reporting person beneficially owns 8,000 shares of PTC Therapeutics common stock in direct ownership. The filing is made on Form 4 for a single reporting person and indicates the shares were donated to a charitable organization.

Positive
  • None.
Negative
  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Okey Stephanie

(Last) (First) (Middle)
C/O PTC THERAPEUTICS, INC.
500 WARREN CORPORATE CENTER DRIVE

(Street)
WARREN NJ 07059

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/20/2025 G(1) 867 D $0 8,000 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents the Reporting Person's bona fide gift of shares of the issuer's common stock to a charitable organization.
/s/ Avraham S. Adler, Attorney-in-Fact 11/21/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PTC Therapeutics (PTCT) report in this Form 4?

The Form 4 reports that a director of PTC Therapeutics, Inc. (PTCT) made a bona fide gift of 867 shares of the company’s common stock to a charitable organization on 11/20/2025.

Did the PTC Therapeutics insider receive cash from this 867-share transaction?

No. The transaction is coded as a gift with a reported price of $0 per share, indicating that the reporting person did not receive cash proceeds from this transfer.

How many PTC Therapeutics (PTCT) shares does the director own after the gift?

Following the reported gift of 867 shares, the director beneficially owns 8,000 shares of PTC Therapeutics common stock, held in direct ownership.

What is the relationship of the reporting person to PTC Therapeutics?

The reporting person is identified as a Director of PTC Therapeutics, Inc., with the Form 4 indicating the filing is made by one reporting person.

What does the Form 4 explanation say about the PTC Therapeutics stock transfer?

The explanation states that the transaction represents the reporting person's bona fide gift of shares of the issuer's common stock to a charitable organization.

Were any derivative securities reported in this PTC Therapeutics Form 4?

No derivative securities were listed as acquired, disposed of, or beneficially owned in Table II of this Form 4.

Ptc Therapeutics

NASDAQ:PTCT

PTCT Rankings

PTCT Latest News

PTCT Latest SEC Filings

PTCT Stock Data

6.14B
78.28M
2.47%
101.79%
8.36%
Biotechnology
Pharmaceutical Preparations
Link
United States
WARREN